Clinical Trials Logo

Nausea clinical trials

View clinical trials related to Nausea.

Filter by:

NCT ID: NCT04240236 Completed - Clinical trials for Postoperative Nausea and Vomiting

Scalp Blocks Effect on Postoperative Nausea & Vomiting After Craniotomy

Start date: October 30, 2019
Phase: N/A
Study type: Interventional

In this study, the investigators hypothesize that preemptive scalp block in neurosurgical patients may decrease incidence of PONV after craniotomy through decreasing intraoperative inhalational agents' concentration and decreasing intraoperative opioids requirements, with better intraoperative hemodynamics and lesser recovery time

NCT ID: NCT04232423 Completed - Clinical trials for Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis

Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

OLN-EME
Start date: March 1, 2020
Phase: Phase 3
Study type: Interventional

To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo

NCT ID: NCT04226976 Suspended - Nausea Clinical Trials

Efficacy of a Non-invasive Vestibular System Masking for Improving Outcomes Following Acute Unilateral Vestibulopathy

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Vestibular disorders are among the most common causes of disability in society and affect over 50% of the population over the age of 65 and a significant percentage of the younger population. Acute unilateral vestibulopathy (AUV) is easy to diagnose and is commonly treated with physical therapy exercises called vestibular rehabilitation. But due to the discomfort experienced during AUV, patients can't usually comply with the treatment plan prescribed by their healthcare provider. In this study, the investigators propose the use of an adjuvant device, the OtoBand, to improve balance, gait, reduce vertigo, and nausea in participants with AUV. Participants enrolled will undergo three vestibular tests batteries: one baseline, one with the OtoBand set at an effective power, and one with the placebo device set at low power. Neither participants nor investigator will know which device is effective and which is placebo. The OtoBand will be set at two different effective power levels. Which power level the participant will receive is randomized and unknown to the participant or investigator.

NCT ID: NCT04201769 Active, not recruiting - Clinical trials for Chemotherapy-induced Nausea and Vomiting

Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin

LUNG-NEPA
Start date: November 25, 2016
Phase: Phase 3
Study type: Interventional

This study evaluates the possibility to reduce the total dose of dexamethasone, when administered with NEPA, to prevent chemotherapy-induced nausea and vomiting (CINV) in Non-Small Cell Lung Cancer (NSCLC) patients receiving a cisplatin-based chemotherapy

NCT ID: NCT04188106 Completed - Stress Clinical Trials

Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment

HAVE
Start date: June 17, 2019
Phase: Phase 4
Study type: Interventional

This open-label study will evaluate hydroxyzine, a first-generation antihistamine, combined with varenicline, to help smokers abstain from smoking during a 12-week trial period by diminishing the nausea, stress, anxiety, and sleep disturbances associated with the use of varenicline and with nicotine withdrawal.

NCT ID: NCT04183842 Completed - Anxiety Clinical Trials

Evaluation of a Fixed Combination of Herbal Extracts to Prevent Symptoms Alcohol-induced Hangovers

LACIME
Start date: July 4, 2019
Phase: N/A
Study type: Interventional

The primary objective of the study is to test whether the tested Product LACIME Anti-hangover is effective in preventing the signs and symptoms of alcohol-induced hangover (such as headache, impaired memory, depression, anxiety, weakness, trouble sleeping and concentrating, nausea, dizziness, sleepiness, thirsty, dry mouth, sweating, sensitivity to light and sounds, vision problems) in healthy subjects.

NCT ID: NCT04182828 Recruiting - Post-operative Pain Clinical Trials

Effect of Intravenous Lidocaine on Immediate Post-operative Pain, Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Placebo Controlled Trial

Start date: November 25, 2019
Phase: Phase 4
Study type: Interventional

Lidocaine is a drug that has multiple uses. One of these is that when intravenously administered it is effective in reducing post-operative pain. The aim of this study is to investigate the beneficial effects of intravenous lignocaine on reducing pain, nausea and vomiting after laparoscopic cholecystectomy. Also, by this research, we are aiming to find a suitable alternative analgesic.

NCT ID: NCT04181346 Recruiting - Nausea Clinical Trials

Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin can improve the complete control of nausea and vomiting (primary end point)

NCT ID: NCT04155931 Completed - Clinical trials for Postoperative Nausea and Vomiting

The Effect of Intraoperative Body Temperature on Postoperative Nausea and Vomiting in Pediatric Patients

Start date: November 7, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of our study was to investigate the effects of changes in body temperature in the perioperative period on postoperative nausea and vomiting.

NCT ID: NCT04150614 Recruiting - Clinical trials for Chemotherapy-induced Nausea and Vomiting

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

Start date: May 14, 2020
Phase: Phase 4
Study type: Interventional

Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.